

Yervoy[®] (ipilimumab) – Expanded indication

- On February 15, 2023, the [FDA approved](#) Bristol Myers Squibb's [Yervoy \(ipilimumab\)](#), in combination with [Opdivo[®] \(nivolumab\)](#), for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.
 - Yervoy was previously approved for this indication in adults only.
- Yervoy is also approved as a single-agent for treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
- In addition to treatment of melanoma, Yervoy is approved for adjuvant treatment of melanoma; advanced renal cell carcinoma; microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer; hepatocellular carcinoma; metastatic non-small cell lung cancer; malignant pleural mesothelioma; and esophageal cancer.
- Refer to the Yervoy drug label for dosing and administration for all its uses and indications.